Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis
- PMID: 31663630
- PMCID: PMC7031559
- DOI: 10.1002/jcla.23057
Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis
Abstract
Background: Renal failure is a severe complication of symptomatic myeloma, related to higher mortality. Recovery from dialysis dependence can lead to enormous survival benefits. We investigated the effect factors for probability of dialysis independence.
Methods: Retrospective data on 45 newly diagnosed MM (NDMM) patients with serious renal impairment and requiring hemodialysis were analyzed. The statistical methods including logistic regression analysis, Kaplan-Meier survival curves, the log-rank test and the Cox proportional hazards model for survival analysis were used in our study.
Results: Twenty-two of the 45 patients, who were on hemodialysis at diagnosis, became dialysis independence. In the logistic regression analysis, serum level of β2-microglobulin, kidney disease history, involved free light chain, and achieving at least VGPR were significantly associated with reversibility from dialysis dependence. In addition, achieving hemodialysis discontinuation was related to better survival. The multivariate analyses demonstrated that reversibility from dialysis dependence, proteinuria < 3.5 g/24 h, and achieving at least VGPR were significantly associated with OS among NDMM patients requiring hemodialysis.
Conclusion: Lower serum level of β2-microglobulin and lower level of free light chain at diagnosis, achieving at least VGPR, and shorter kidney disease history are related to a high probability of dialysis independence in NDMM patients with serious renal failure requiring dialysis.
Keywords: dialysis independence; effect factors; hemodialysis; multiple myeloma; renal failure.
© 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc.
Figures


Similar articles
-
Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.Am J Hematol. 2016 May;91(5):499-502. doi: 10.1002/ajh.24335. Epub 2016 Apr 4. Am J Hematol. 2016. PMID: 26890495 Clinical Trial.
-
Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.Clin J Am Soc Nephrol. 2009 Apr;4(4):745-54. doi: 10.2215/CJN.04590908. Epub 2009 Apr 1. Clin J Am Soc Nephrol. 2009. PMID: 19339414 Free PMC article. Clinical Trial.
-
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis.Clin Lymphoma Myeloma Leuk. 2025 Jul;25(7):532-538. doi: 10.1016/j.clml.2025.03.003. Epub 2025 Mar 4. Clin Lymphoma Myeloma Leuk. 2025. PMID: 40122729
-
Renal failure in multiple myeloma: a medical emergency.Bone Marrow Transplant. 2011 Jun;46(6):771-83. doi: 10.1038/bmt.2011.8. Epub 2011 Feb 21. Bone Marrow Transplant. 2011. PMID: 21339749 Review.
-
[Survival of myeloma patients treated with dialysis].Nefrologia. 2003;23(2):131-6. Nefrologia. 2003. PMID: 12778877 Review. Spanish.
Cited by
-
Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.J Clin Lab Anal. 2020 Jun;34(6):e23233. doi: 10.1002/jcla.23233. Epub 2020 Feb 10. J Clin Lab Anal. 2020. PMID: 32039495 Free PMC article.
-
Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study.Clin Exp Med. 2025 Feb 4;25(1):48. doi: 10.1007/s10238-025-01571-9. Clin Exp Med. 2025. PMID: 39904814 Free PMC article.
References
-
- Wirk B. Renal failure in multiple myeloma: a medical emergency. Bone Marrow Transplant. 2011;46:771‐783. - PubMed
-
- Dimopoulos MA, Terpos E, Chanan‐Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28:4976‐4984. - PubMed
-
- Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma‐Related Renal Impairment. J Clin Oncol. 2016;34:1544‐1557. - PubMed
-
- Davenport A, Merlini G. Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. Nephrol Dial Transplant. 2012;27:3713‐3718. - PubMed
-
- Tsakiris DJ, Stel VS, Finne P, et al. Incidence and outcome of patients starting renal replacement therapy for end‐stage renal disease due to multiple myeloma or light‐chain deposit disease: an ERA‐EDTA Registry study. Nephrol Dial Transplant. 2010;25:1200‐1206. - PubMed
MeSH terms
Grants and funding
- 81570106, 814000888, 81600093, 81900131/National Natural Science Foundation of China
- 14JCYBJC25400, 15JCYBJC24300,18JCQNJC80400/the Tianjin Municipal Natural Science Foundation
- 12ZCDZSY18000/the anticancer major special project of Tianjin
- 15KG150/Tianjin Health and Family Planning Commission
- 2018KJ043, 2018KJ045/Tianjin Education Commission Research Project
LinkOut - more resources
Full Text Sources
Medical